Systematic (IUPAC) name | |
---|---|
3-((6R)-6-{[(4-Chlorophenyl)sulfonyl]amido}-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoic acid | |
Identifiers | |
CAS number | 165538-40-9 609340-89-8 (sodium salt) |
ATC code | None |
PubChem | CID 9938840 |
Chemical data | |
Formula | C20H22ClNO4S |
Mol. mass | 407.911 g/mol |
SMILES | eMolecules & PubChem |
InChI=1S/C20H22ClNO4S/c1-13-2-3-14-12-16(6-9-19(14)18(13)10-11-20(23)24)22-27(25,26)17-7-4-15(21)5-8-17/h2-5,7-8,16,22H,6,9-12H2,1H3,(H,23,24)/t16-/m1/s1
Key: HWEOXFSBSQIWSY-MRXNPFEDSA-N |
|
Pharmacokinetic data | |
Half-life | 6–10 hours |
Therapeutic considerations | |
Pregnancy cat. | ? |
Legal status | Investigational |
Routes | Oral |
Terutroban is an antiplatelet agent developed by Servier Laboratories. As of 2010, it is being tested for the secondary prevention of acute thrombotic complications in the Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack).[1]
Method of action
Terutroban is a selective antagonist of the thromboxane receptor. It blocks thromboxane induced platelet aggregation and vasoconstriction.[2][3]
References
- ^ Hennerici, M. G.; Bots, M. L.; Ford, I.; Laurent, S.; Touboul, P. J. (2010). "Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial". Cardiovascular Drugs and Therapy 24 (2): 175. doi:10.1007/s10557-010-6231-2. PMID 20490906.
- ^ H. Spreitzer (January 29, 2007). "Neue Wirkstoffe - Terutroban" (in German). Österreichische Apothekerzeitung (3/2007): 116.
- ^ Sorbera, LA, Serradell, N, Bolos, J, Bayes, M (2006). "Terutroban sodium". Drugs of the Future 31 (10): 867–873. doi:10.1358/dof.2006.031.10.1038241.
|